The 200Tx device provides visualisation of ultra-widefield autofluorescence changes to retinal pigment epithelium (RPE), the pigmented cell layer just outside the neurosensory retina that nourishes retinal visual cells.

The 200Tx offers multiple wavelength imaging including options for colour, red-free, fluorescein angiography and autofluorescence, each of which can reveal different pathologies, Optos said. 

The device also provides simultaneous pole to periphery views of more than 80% or 200 degrees of the retina in a single capture, helping physicians discover evidence of disease and guide treatment decisions.

Optos CEO Roy Davis said that through their work with researchers they have further proven the value their technology provides in detecting diseases and pathologies that may first be seen in the periphery of the retina and they look forward to the launch of 200Tx model in Q1 2011.